Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy

NCT04249362 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04249362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04249362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multicenter, International Study of Durvalumab Following Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer Who Are Ineligible for Chemotherapy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
November 26, 2020
Completion date
November 25, 2024
Enrollment
102 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer